These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 16156677)

  • 21. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease therapy: treatment of early and late disease.
    Jankovic J
    Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
    ; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
    Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy.
    Hauser RA
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S17-21. PubMed ID: 20082983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
    Jann MW
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S315-21. PubMed ID: 22087552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease: drug therapy.
    Oertel WH; Quinn NP
    Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for current therapies in Parkinson's disease.
    Romrell J; Fernandez HH; Okun MS
    Expert Opin Pharmacother; 2003 Oct; 4(10):1747-61. PubMed ID: 14521485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
    Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
    Jost WH
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic substitution in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.